Are vascular factors involved in Alzheimer's disease? Facts and theories

Aging Clinical and Experimental Research

Volumn 11, Issue 6, 1999, Pages 345-352

  Di Iorio, A ^a   Zito, M ^a   Lupinetti, M ^a   Abate, G ^a,b  

^a UNIVERSITY OF CHIETI   (Italy)

^b Allergy and Clinical Immunology   (Italy)

Author keywords

Alzheimer's disease; Hypertension; Vascular factors

Indexed keywords

AMYLOID; ANTIHYPERTENSIVE AGENT;

ALZHEIMER DISEASE; BRAIN ISCHEMIA; DEGENERATIVE DISEASE; DEMENTIA; DIABETES MELLITUS; HYPERINSULINEMIA; HYPERTENSION; MULTIINFARCT DEMENTIA; NEUROFIBRILLARY TANGLE; REVIEW; SENILE PLAQUE; SMOKING; VASCULAR AMYLOIDOSIS; VASCULAR DISEASE;

EID: 0033500249     PISSN: 03949532     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03339811     Document Type: Review

References (85)

1. American Psychiatric Association: Diagnostic and statistical manual of mental disorders, 4th ed. revised. Washington, DC, APA, 1996.
2. McKhann G., Drachman D., Folstein M.: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA. Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944, 1984.
3. White L.: Is silent cerebrovascular disease an important cause of late-life cognitive decline? J. Am. Geriatr. Soc. 44: 328-330, 1996.
4. Elias M.F.: Effects of chronic hypertension on cognitive functioning. Geriatrics 53 (Suppl. 1): S49-S52, 1998.
5. Elias M.F., Wolf P.A., D'Agostino R.B.: Untreated blood pressure level is inversely related to cognitive functioning. The Framingham Study. Am. J. Epidemiol. 138: 353-364, 1993.
6. Kilander L., Nyman H., Boberg M., Hansson L., Lithell H.: Hypertension is related to cognitive impairment. A 20-years follow-up of 999 men. Hypertension 31: 780-786, 1998.
7. Launer L.J., Masaki K., Petrovitch H.: The association between midlife blood pressure levels and late life cognitive function. JAMA 274: 1846-1851, 1995.
8. Palombo V., Scurti R., Muscari A., Puddu G.M., Di Iorio A., Zito M., Abate G.: Blood pressure and intellectual function in elderly subjects. Age Ageing 26: 91-98, 1997.
9. Skoog I., Lemfelt B., Landahl S.: 15-year longitudinal study of blood pressure and dementia. Lancet 349: 151-154, 1997.
10. Skoog I., Landahl S., Lernfelt B.: High blood pressure and dementia. Lancet 348: 65-66, 1996 (Letter).
11. Skoog I., Andreasson L., Landhal S., Lernfelt B.: A population-based study on blood pressure and brain atrophy in 85-years olds. Hypertension 32: 404-409, 1998.
12. Guo Z., Vitanen M., Fratiglioni L.: Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ 312: 805-808, 1996.
13. Leibson C.L., Rocca W.A., Hanson V.A.: Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am. J. Epidemiol. 145: 301-308, 1997.
14. Yoshitake T., Kiyohara Y., Kato I.: Incidence and risk factors of vascular dementia and Alzheimer's disease in defined elderly Japanese population. The Hisayama Study. Neurology 45: 1161-1168, 1995.
15. Yan S.D., Chen X., Fu J.: RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease patients. Stroke 27: 2069-2074, 1996.
16. Mooradian A.D.: Blood-brain barrier choline transport is reduced in diabetic rats. Diabetes 36: 1094-1097, 1987.
17. Kuusisto J., Koivisto K., Mykkanen L., Helkala E.L., Vanhanen M., Hanninen T., Pyorala K., Rikkinen P., Laakso M.: Essential hypertension and cognitive function. The role of hyperinsulinemia. Hypertension 22: 771-779, 1993.
18. Kuusisto J., Koivisto K., Mykkanen L.: Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: Cross sectional population based study. BMJ 315: 1045-1049, 1997.
19. Palovcik R.A., Phillips M.I., Kappy M.S.: Insulin inhibits pyramidal neurons in hippocampal slices. Brain Res. 309: 187-191, 1984.
20. Brass B.J., Nonner D., Barret J.N.: Differential effects of insulin on choline acetyltransferase and glutamic acid decarboxilase activities in neuron-rich striatal cultures. J. Neurochem. 59: 415-424, 1992.
21. Hong M., Lee V.M.Y.: Insulin and insulin-like growth factor-1 regulate tau phoshorylation in cultured human neurons. J. Biol. Chem. 272: 1947-1953, 1997.
22. Unger J., McNeill T.H., Moxley R.T.: Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience 31: 143-147, 1989.
23. Landin K., Blennow K., Wallin A.: Low blood pressure and blood glucose levels in Alzheimer's disease. Evidence for a hypometabolic disorder? J. Intern. Med. 233: 357-363, 1993.
24. Wolf-Klein G.P., Silverstone F.A., Brod M.S.: Are Alzheimer patients healthier? J. Am. Geriatr. Soc. 36: 219-224, 1988.
25. Hofman A., Ott A., Breteler M.M.B.: Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349: 151-154, 1997.
26. Scott R.D., Krits-Silverstein D., Barrett-Connor E., Wiederholt W.C.: The association of non-insulin-dependent diabetes mellitus and cognitive function in an older cohort. J. Am. Geriatr. Soc. 46: 1217-1222, 1998.
27. Graves A.B., Van Duijn C.M., Chandra V.: Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. Int. J. Epidemiol. 20 (Suppl. 2): S48-S57, 1991.
28. Prince M., Cullen M., Mann A.: Risk factors for Alzheimer's disease and dementia: a case-control study based on the MRC elderly hypertension trial. Neurology 44: 97-104, 1994.
29. Brenner D.E., Kukull W.A., Van Belle G., Bowen J.D., McCormick W.C., Teri L., Larson E.B.: Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am. J. Epidemiol. 140: 262-267, 1994.
30. Whitehouse P.J., Kalaria R.N.: Nicotine receptors and neurodegenerative dementing diseases: basic research and clinical implications. Alzheimer Dis. Assoc. Disord. 9 (Suppl. 2): 3-5, 1995.
31. Wilson A.L., Langley L.K., Monley J., Bauer T., Rottunda S., McFalls E., Kovera C., McCarten J.R.: Nicotine patches in Alzheimer's disease: pilot study on learning, memory and safety. Pharmacol. Biochem. Behav. 51: 509-514, 1995.
32. Canadian Study of Health and Aging Working Group. The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada. Neurology 44: 2073-2080, 1994.
33. Forster D.P., Newens A.J., Kay D.W., Edwardson J.A.: Risk factors in clinically diagnosed presenile dementia of the Alzheimer type: a case-control study in northern England. J. Epidemiol. Community Health 49: 253-258, 1995.
34. Fielding J.E.: Smoking: health effect and control. N. Engl. J. Med. 313: 555-561, 1985.
35. Ferrucci L., Guralnik J.M., Salive M.E.: Cognitive impairment and risk of stroke in the older population. J. Am. Geriatr. Soc. 44: 237-241, 1996.
36. Moroney J.T., Desmond D.W: Cognitive impairment and risk of stroke in the older population. J. Am. Geriatr. Soc. 44: 1410-1411, 1996 (Letter).
37. Ott A., Breteler M.M.B., de Bruyne M.C.: Atrial fibrillation and dementia in a population based study. Stroke 28: 316-321, 1997.
38. Kalman J., Juhasz A., Csaszar A., Kanka A., Rimanoczy A., Janka Z., Rasko I.: Increased apolipoprotein E4 allele frequency is associated with vascular dementia in the Hungarian population. Acta Neurol. Scand. 98: 166-168, 1998.
39. Noguchi S., Murakami K., Yamada N.: Apolipoprotein E genotype and Alzheimer's disease. Lancet 342: 737-741, 1993.
40. Nagy Z.S., Esiri M.M., Joachim C., Jobst K.A., Morris J.H., King E.M., Hindley N.J., McDonald B., Litchfield S., Barnetson L., Smith A.D.: Comparison of pathological diagnostic criteria for Alzheimer disease. Alzheimer Dis. Assoc. Disord. 12: 182-189, 1998.
41. Morris J.C., Storandt M., McKeel D.W., Rubin E.H., Price J.L., Grant E.A., Berg L.: Cerebral amyloid deposition and diffuse plaques in "normal" aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology 46: 707-719, 1996.
42. Haroutunian V., Perl D.P., Purohit D.P., Marin D., Khan K., Lantz M., Davis K.L., Mohs R.C.: Regional distribution of neuritic plaques in the non demented elderly and subjects with very mild Alzheimer disease. Arch. Neurol. 55: 1185-1191, 1998.
43. Ellis R.J., Olichney J.M., Thal L.J., Mirra S.S., Morris J.C., Beekly D., Heyman A.: Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience. Part XV. Neurology 46: 1592-1596, 1996.
44. Kalaria R.N., Hedera P.: β-amyloid vasoactivity in Alzheimer's disease. Lancet 347: 1492-1493, 1996 (Letter).
45. de la Torre J.C., Mussivand T.: Can disturbed brain microcirculation cause Alzheimer's disease? Neurol. Res. 15: 146-153, 1993.
46. Sutton E.T., Hallermann G.R., Thomas T.: β-Amyloid induced endothelial necrosis and inhibition of nitric oxide production. Exp. Cell Res. 230: 368-376, 1997.
47. Olichney Y.M., Hansen L.A., Hofstetter C.R.: Cerebral infarction in Alzheimer's disease is associated with severe amyloid angiopathy and hypertension. Arch. Neurol. 52: 703-708, 1995.
48. Iwamoto N., Nishiyama E., Ohwada J.: Distribution of amyloid deposits in the cerebral white matter of the Alzheimer's disease brain: relationship to blood vessels. Acta Neuropathol. 93: 334-340, 1997.
49. Brillian M., Hughes L., Anderson D., Ghobrial M., Elble R.: Rarefied white matter in patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 9: 39-46, 1995.
50. Golomb J., Kluger A., Gianutsos J., Ferris S.H., de Leon M.J., George A.E.: Non specific leukoencephalopathy associated with aging. Neuroimaging Clin. J. Am. 5: 33-44, 1995.
51. George A.E., de Leon M.J., Gentes C.I., Miller J., London E., Budzilovich G.N.: Leukoencephalopathy in normal and pathological ageing. Am. J. Neuroradiol. 7: 561-566, 1986.
52. Wallin A., Blennow K., Uhlemann C., Langstrom F., Gottfries C.G.: White matter low attenuations on CT in Alzheimer's disease and vascular dementia; diagnostic and pathogenetic aspects. Acta Neurol. Scand. 80: 518-523, 1989.
53. Inzitari D., Diaz F., Fox A., Hachinski V.C., Steingart A., Lau C.: Vascular risk factors and leukoaraiosis. Arch. Neurol. 44: 42-47, 1987.
54. Amar K., Wilkock G.: Vascular dementia. BMJ 312: 227-231, 1996.
55. Blennow K., Wallin A., Uhlemann C., Gottfries C.G.: White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. Acta Neurol. Scand. 83: 187-193, 1991.
56. Furuta A., Nobuyoshi I., Nischihara Y., Horie A.: Medullary arteries in aging and dementia. Stroke 22: 442-446, 1991.
57. Roman G.C.: Senile dementia of the Binswanger type: a vascular form of dementia in the elderly. JAMA 258: 1782-1788, 1987.
58. Pantoni L., Garcia J.H.: Pathogenesis of leukoaraiosis: a review. Stroke 28: 652-659, 1997.
59. Brun A., Englund E.: A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann. Neurol. 19: 253-262, 1986.
60. Tumimoto H., Akiguchi I., Suenaga T., Nishimura M., Wakita H., Nakamura S., Kimura J.: Alterations of the blood-brain barrier and glial cells in white-matter lesions in cerebrovascular and Alzheimer's disease patients. Stroke 27: 2069-2074, 1996.
61. Hann J., Rooss R.A., Algra P.R.: Hereditary cerebral haemorrhage with amyloidosis-Dutch type. Magnetic resonance imaging findings in 7 cases. Brain 113: 1251-1267, 1990.
62. Erkinjuntti T., Benavente O., Eliasziw M.: Diffuse vacuolization (spongiosis) and arteriosclerosis in the frontal white matter occurs in vascular dementia. Arch. Neurol. 53: 325-332, 1996.
63. Steward R.: Cardiovascular factors in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 65: 143-147, 1998.
64. Breteler M.M.B., Van Swieten J.C., Bots M.L., Grobbee D.E., Claus J.J., Van Den Hout J.H.W., Van Harskamp F., Tanghe H.L.J., De Jong P.T.V.M., Van Gijn J., Hofman A.: Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study. The Rotterdam Study. Neurology 44: 1246-1252, 1994.
65. Smowdon D.A., Greiner L.H., Mortimer J.A., Riley K.P., Greiner P.A., Markesbery W.R.: Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277: 813-817, 1997.
66. Sparks D.L., Scheff S.W., Liu H.: Increased incidence of neurofibrillary tangles in non-demented individuals with hypertension. J. Neurol Sci. 131: 162-169, 1995.
67. Strassburger T.L., Lee H.C., Daly E.M., Szezepanic J., Krasuski J.S., Mentis M.J., Salerno J.A., DeCarli C., Shapiro M.B., Alexander G.E.: Interactive effects of age and hypertension on volume of brain structures. Stroke 28: 1410-1417, 1997.
68. Brun A., Gustafson L., Samulsson S.M., Ericsson C.: Neuropathology of late life. Dementia 3: 125-130, 1992.
69. Hulette C., Nochlin D., McKeel D.: Clinical-neuropathologic findings in multi-infarct dementia: a report of six autopsied cases. Neurology 48: 668-672, 1997.
70. Desmond D.W.: Vascular dementia: a construct in evolution. Cerebrovasc. Brain Metab. Rev. 8: 296-325, 1996.
71. Nolan K.A., Lino M.M., Seligmann A.W., Blass J.P.: Absence of vascular dementia in an autopsy series from a dementia clinic. J. Am. Geriatr. Soc. 46: 597-604, 1998.
72. Nyenhuis D.L., Gorelick P.B.: Vascular dementia: a contemporary review of epidemiology, diagnosis, prevention and treatment. J. Am. Geriatr. Soc. 46: 1437-1448, 1998.
73. Hall E.D., Osteveen J.A., Dunn E.: Increased amyloid protein precursor and apolipoprotein E immunoreactivity in the selectively vulnerable hippocampus following transient forebrain ischemia in gerbils. Exp. Neurol. 135: 17-27, 1995.
74. Pluta R., Barcikowsa M., Janusezewki S.: Evidence of blood-brain barrier permeability/leakage for circulating human Alzheimer's β-amyloid (1-42) peptide. Neuroreport 7: 1261-1265, 1996.
75. Sasaki N., Fakatsu R., Tsuzuki K., Yoshida T., Fujii N., Koike T., Wakayama I., Yanagihara R., Garruto R., Amano N., Makita Z.: Advanced glycation end products in Alzheimer's disease and other neurodegenerative disease. Am. J. Pathol. 153: 1149-1155, 1998.
76. Forette F., Seux M.L., Staessen J.A., Thijs L., Birkenhager W.H., Babarskiene M.R., Babeanu S., Bossini A., Gil-Extremera B., Girerd X., Laks T., Lilov E., Moisseyev V., Tuomileto J., Vanhanen H., Webster J., Yodfat Y., Fagard R.: Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352: 1347-1351, 1998.
77. Shep Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the systolic hypertension in the Elderly Program (SHEP). JAMA 265: 3255-3264, 1991.
78. Parnetti L., Senin U., Mecocci P.: Cognitive enhancement therapy for Alzheimer's disease: the way forward. Drugs 53: 752-768, 1997.
79. Gould R.J., Murphy K.M., Snyder S.H.: Autoradiographic localization of calcium channel antagonist receptors in rat brain with (3H) nitrendipine. Brain Res. 330: 217-223, 1985.
80. Barrett-Connor E.: Rethinking estrogen in the brain. J. Am. Geriatr. Soc. 46: 918-920, 1998.
81. Yaffe K., Grady D., Pressman A., Cummings S.: Serum estrogen levels, cognitive performance, and risk of cognitive decline in older community women. J. Am. Geriatr. Soc. 46: 816-821, 1998.
82. Trabucchi M.: Le demenze. UTET, Milano, 1998.
83. McGeer P.L., Schulzer M., McGeer E.G.: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47: 425-432, 1996.
84. Rich J.B., Rasmusson D.X., Folstein M.F.: Non-steroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45: 51-55, 1995.
85. Steward W.F., Kawas C., Corrada M.: Risk of Alzheimer's disease and duration of NSAID use. Neurology 48: 626-632, 1997.